GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Tango Therapeutics
Tango Therapeutics is a biotech company developing cancer treatments based on the concept of synthetic lethality. Its stock price represents a venture bet on a breakthrough in genetically targeted oncology. The chart reflects news from its lab and clinical trials.
Share prices of companies in the market segment - Oncology immuno-therapy
Tango Therapeutics (TNGX) is a biotech company using genetics to discover and develop new cancer treatments targeting so-called "synthetic lethality." We classify the company as "Immuno-oncology." The chart below illustrates the dynamics of this cutting-edge and risky biotech sector.
Broad Market Index - GURU.Markets
Tango Therapeutics is an oncology company developing drugs based on the concept of synthetic lethality for the targeted destruction of cancer cells. As a component of the GURU.Markets index, it represents the cutting edge of medicine. The chart below represents the entire market. Evaluate how this innovator compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
TNGX - Daily change in the company's share price Tango Therapeutics
Shares of Tango Therapeutics, an oncology company, are highly volatile. Change_co measures market reaction to preclinical and early clinical trial data. This metric is an essential component in building valuation models for cutting-edge companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Oncology immuno-therapy
Tango Therapeutics, Inc. is an oncology company. This chart highlights the extreme volatility of the biotech sector. Comparison with TNGX's clinical trial-driven performance helps to assess it as a high-risk asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Tango is a biopharmaceutical company developing targeted therapies for cancer. Oncology is a highly volatile sector driven by clinical trial results. The chart below reflects average fluctuations in this industry, providing context for evaluating Tango stock.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Tango Therapeutics
Tango is a biotech company developing cancer immunotherapy drugs. Its shares are buoyed by anticipation of clinical trial results. These sharp, event-driven movements are part of a complex mosaic of stock market volatility.
Annual dynamics of market capitalization of the market segment - Oncology immuno-therapy
Tango Therapeutics, Inc. is a biotech company developing cancer treatments based on the concept of synthetic lethality. Its stock performance is entirely dependent on clinical trial results. The chart reflects the high risks and potential for breakthroughs in this cutting-edge field of oncology.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tango Therapeutics is a clinical-stage biotech whose fate depends on scientific breakthroughs, not the state of the economy. Its stock price reflects investor hopes for the success of new drug trials. The company's chart exists in a world of its own, where the main events are data releases.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Tango Therapeutics
Tango, a biopharmaceutical company, is a speculative company. Its monthly fluctuations reflect not revenue, but rather news about the progress of clinical trials of its oncology drugs based on the concept of synthetic lethality, the success of which determines its entire future valuation.
Monthly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Tango Therapeutics is developing a new generation of cancer drugs using the concept of "synthetic lethality" to precisely target tumor cells. The company's valuation reflects investors' faith in its scientific platform. The chart below shows general trends in the immuno-oncology sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Tango Therapeutics is a biotech company developing targeted cancer therapies. Its stock, like other research-stage companies, moves based on scientific data and news about clinical trials. Its performance is completely disconnected from the broader market and is a bet on a scientific breakthrough.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Tango Therapeutics
The short-term price fluctuations of Tango Therapeutics, an early-stage oncology company, are entirely dependent on scientific news. Any preclinical data, announcements of progressing to human trials, or news from competitors in the field of synthetic lethality trigger sharp price movements.
Weekly dynamics of market capitalization of the market segment - Oncology immuno-therapy
Tango Therapeutics shares, like those of the entire oncology biotech sector, are driven by sector-wide news and sentiment. Breakthroughs in immunotherapy or changes in FDA policy could boost the entire industry. The chart will show how the company stacks up against this high-risk segment.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Biotech companies like Tango Therapeutics often live in their own world, isolated from broader market fluctuations. Their stocks' fortunes are determined by clinical trial news, not inflation reports. The chart will show how often their stocks move against the broader market tide.
Market capitalization of the company, segment and market as a whole
TNGX - Market capitalization of the company Tango Therapeutics
The Tango Therapeutics market capitalization chart represents the financial valuation of a biotech company using a cutting-edge "synthetic lethality" approach to developing targeted cancer drugs. It reflects investor expectations for its scientific platform. Its speculative dynamics tell the story of how the market evaluates the potential of a new generation of oncology drugs.
TNGX - Share of the company's market capitalization Tango Therapeutics within the market segment - Oncology immuno-therapy
Tango Therapeutics is an oncology company developing drugs based on the concept of "synthetic lethality," which enables the killing of cancer cells with specific genetic mutations. Its position in the biotech sector is based on this cutting-edge approach. The chart shows the potential of its targeted therapy.
Market capitalization of the market segment - Oncology immuno-therapy
Tango Therapeutics is using synthetic lethality to develop a new class of cancer drugs. The chart below shows the overall market capitalization of the immuno-oncology sector, reflecting the search for new treatment approaches. In this scientific race, Tango is betting on advanced genetics to target tumors.
Market capitalization of all companies included in a broad market index - GURU.Markets
The oncology sector, visible in the chart, is seeking new treatment approaches. Tango Therapeutics is developing drugs based on the concept of "synthetic lethality," which targets cancer cells with specific genetic mutations. Its capitalization represents a risky bet on this cutting-edge scientific approach.
Book value capitalization of the company, segment and market as a whole
TNGX - Book value capitalization of the company Tango Therapeutics
Tango Therapeutics's chart represents capital for targeted cancer therapy. The company's research-stage book value consists of financial reserves. These assets are used to develop drugs that target cancer cell vulnerabilities known as "synthetic lethality."
TNGX - Share of the company's book capitalization Tango Therapeutics within the market segment - Oncology immuno-therapy
Tango Therapeutics, a biotech company, is developing a new generation of cancer drugs. Its stake in the sector's assets includes cutting-edge genetic research laboratories. The chart shows that the company is building a scientific foundation by investing in the physical infrastructure for discovery.
Market segment balance sheet capitalization - Oncology immuno-therapy
Tango Therapeutics is an oncology company. Pharmaceuticals, as the chart shows, are both knowledge- and capital-intensive. Tango focuses on drug development, and its capital is intellectual property and R&D infrastructure for clinical trials.
Book value of all companies included in the broad market index - GURU.Markets
Tango Therapeutics is a biotech company developing a new class of cancer drugs based on the concept of "synthetic lethality." Its book value is the capital it invests in its scientific platform and clinical trials.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Tango Therapeutics
Tango Therapeutics is an oncology biotech. Its market capitalization is a premium to its cash flow, reflecting investors' bet on the success of its "synthetic lethality" scientific platform.
Market to book capitalization ratio in a market segment - Oncology immuno-therapy
Tango Therapeutics is developing a new generation of targeted cancer treatments based on genetics. This is cutting-edge science. The chart shows that the company's market value is based on expectations of future breakthroughs in oncology, not on its current, rather modest, tangible assets.
Market to book capitalization ratio for the market as a whole
Tango Therapeutics is a biotech company developing cancer treatments based on the concept of "synthetic lethality." Compared to average market valuations shown in this chart, its high premium is speculative and based on the potential of its precise genetic approach to drug discovery.
Debts of the company, segment and market as a whole
TNGX - Company debts Tango Therapeutics
Tango Therapeutics is a biotechnology company developing a new generation of targeted cancer therapies. Currently in preclinical and early clinical trials, the company relies entirely on private equity capital. This chart shows how Tango funds its innovative cancer genetics research to develop future treatments.
Market segment debts - Oncology immuno-therapy
Tango Therapeutics is a biotech company developing a new class of cancer drugs. Being in clinical trials, it has no revenue. Its debt policy is likely to be very conservative. This chart shows how the company uses equity capital to fund its cutting-edge research.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Tango Therapeutics
Tango Therapeutics is a biotech company developing genetically based cancer treatments. This chart shows how it funds its research. For a company without sales revenue, debt is a high-risk factor. Its financial viability depends on its ability to raise equity capital before bringing its drugs to market.
Market segment debt to market segment book capitalization - Oncology immuno-therapy
Tango Therapeutics is a biotech company developing next-generation cancer drugs based on genetic targets. Oncology research is one of the most capital-intensive fields. This chart shows the overall debt burden in the sector, allowing us to assess how Tango finances its cutting-edge, yet expensive, research programs.
Debt to book value of all companies in the market
Tango Therapeutics, Inc. is a biotech company developing a new generation of cancer drugs. Its approach is based on genetics. Being in the research stage, the company is entirely dependent on investor capital. This chart shows that traditional debt instruments are not suitable for financing such cutting-edge, yet risky, scientific research.
P/E of the company, segment and market as a whole
P/E - Tango Therapeutics
For Tango Therapeutics, a clinical-stage oncology company, P/E is not a meaningful metric. It has no products or revenue. Any values on the chart are random. Investors evaluate the company solely on the scientific potential of its platform for developing new cancer drugs.
P/E of the market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company using the concept of synthetic lethality to discover new targeted cancer drugs. This chart shows the average valuation for the sector, helping to understand how the market values this cutting-edge scientific approach to cancer drug development.
P/E of the market as a whole
Tango Therapeutics is a biotech company developing cancer treatments based on the concept of synthetic lethality. Its valuation is a pure bet on the success of its scientific platform and clinical trials. Overall market sentiment, reflected in this chart, is completely irrelevant. Its fate is decided in the lab.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Tango Therapeutics
Tango Therapeutics is a biotech company developing a new class of targeted cancer drugs based on the concept of synthetic lethality. Its valuation depends on the success of this cutting-edge scientific idea. This chart reflects investor expectations regarding future breakthroughs in oncology and the commercial potential of the company's developments.
%20P%2FE%20Tango%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Tango-Therapeutics&v=1772630131895 "Chart of the company's future (projected) P/E Tango Therapeutics")
Future (projected) P/E of the market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. The chart reflects average profitability expectations for the oncology segment. TNGX's position relative to this benchmark reflects investors' bet on their cutting-edge scientific approach to discovering new targets in cancer cells.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Oncology-immuno-therapy&v=1772630131941 "Future (projected) P/E graph of the market segment - Oncology immuno-therapy")
Future (projected) P/E of the market as a whole
Tango Therapeutics is a biotech company developing cancer treatments based on genetic data. This is at the cutting edge of science, and the company's valuation is a bet on future success. This chart shows how willing investors are to fund such high-risk, yet potentially breakthrough, scientific approaches.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772630132017 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Tango Therapeutics
Tango Therapeutics is a biotech company using genetics to discover and develop new cancer drugs. Its approach is based on the concept of "synthetic lethality." Its financials reflect significant investment in research, and future profits depend on the success of its innovative platform.
Profit of companies in the market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. This chart shows the overall profitability of the immuno-oncology sector. It reflects the willingness of investors to fund cutting-edge scientific concepts and how the sector as a whole is progressing in developing more precise cancer treatments.
Overall market profit
Tango Therapeutics is developing a new generation of targeted cancer therapies based on genetics. This is a cutting-edge field of science that requires significant investment. The company's success depends on scientific breakthroughs. However, the overall economic situation, as illustrated by this chart, influences investor risk appetite and the availability of capital to fund long-term R&D projects.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Tango Therapeutics
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. Future profits depend on the success of its R&D. This chart shows analyst expectations regarding the potential of this cutting-edge scientific platform for creating effective oncology drugs.
%20profit%20of%20the%20company%20Tango%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Tango-Therapeutics&v=1772630132088 "Graph of future (projected) profit of the company Tango Therapeutics")
Future (predicted) profit of companies in the market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. Its success depends on the results of clinical trials. This chart reflects forecasts for the biotech sector, helping to assess the potential of Tango's innovative approach to personalized oncology.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Oncology-immuno-therapy&v=1772630132118 "Graph of future (predicted) profits of companies in a market segment - Oncology immuno-therapy")
Future (predicted) profit of the market as a whole
Tango Therapeutics is a biotech company developing targeted cancer therapies. Like other R&D-stage companies in the sector, its success depends on clinical trial results rather than macroeconomic conditions. This overall corporate profit curve is virtually irrelevant to the company.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772630132134 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Tango Therapeutics
Tango Therapeutics is a biotech company developing a new generation of cancer drugs based on genetic data. Being in the early stages, it has almost no revenue. This chart shows the huge advances investors are making to its scientific platform. Its growth depends entirely on progress in preclinical and early clinical trials.
P/S market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company using synthetic lethality to discover and develop new cancer treatments. Future revenue depends on the success of its research. This chart for the oncology sector compares investor expectations for Tango's innovative scientific platform with those of other players in the field of targeted therapy.
P/S of the market as a whole
Tango Therapeutics is a biotech company using the concept of "synthetic lethality" to develop a new class of targeted cancer therapies. This approach targets tumors' genetic vulnerabilities. This market revenue valuation chart helps understand how highly investors value this cutting-edge scientific approach and its potential in oncology.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Tango Therapeutics
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies using the concept of synthetic lethality. This chart shows how the market assesses the future commercial potential of its scientific discoveries. It reflects investor expectations for clinical trial success and the development of breakthrough drugs.
%20P%2FS%20Tango%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Tango-Therapeutics&v=1772630132237 "The graph of the company's future (projected) P/S Tango Therapeutics")
Future (projected) P/S of the market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. The company's valuation is based on investors' faith in its scientific platform and ability to identify new vulnerabilities in cancer cells, which opens up significant, yet risky, opportunities.
%20P%2FS%20market%20segment%20graph%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Oncology-immuno-therapy&v=1772630132329 "Future (projected) P/S market segment graph - Oncology immuno-therapy")
Future (projected) P/S of the market as a whole
Tango Therapeutics is a biotech company developing a new class of targeted cancer treatments. Its approach is based on genetic data. Given the overall revenue projections shown in the chart, Tango represents a venture capital investment in the future of personalized oncology.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772630132353 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Tango Therapeutics
Tango Therapeutics is a biotech company focused on oncology and using a "synthetic lethality" approach to create new drugs. Currently in clinical trials, the company has no commercial products, and any revenue shown in the chart likely comes from upfront payments from partners.
Sales of companies in the market segment - Oncology immuno-therapy
Tango Therapeutics (TNGX) is a biotech company developing a new generation of targeted cancer treatments. Its approach is based on the concept of "synthetic lethality," whereby a drug kills only cancer cells with specific genetic mutations. This metric reflects revenue in the immuno-oncology sector, where Tango is at the forefront of science.
Overall market sales
Tango Therapeutics is a biotech company developing a new generation of cancer drugs based on genetic data. Its development requires significant investment. This chart, reflecting the overall state of the economy and stock markets, affects the availability of capital for the biotech sector. During periods of growth, investors are more willing to fund breakthrough but risky scientific research.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Tango Therapeutics
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. Its future revenue depends on the success of its clinical trials. This chart reflects analyst forecasts, which assess the potential of its innovative scientific platform for the development of new oncology drugs.
%20sales%20of%20the%20company%20Tango%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Tango-Therapeutics&v=1772630132858 "Schedule of future (projected) sales of the company Tango Therapeutics")
Future (projected) sales of companies in the market segment - Oncology immuno-therapy
Tango Therapeutics is a biopharmaceutical company developing cancer treatments based on the concept of synthetic lethality. This graph shows the potential future revenue from their portfolio of targeted oncology drugs. This is an analyst's perspective on the commercial prospects of this cutting-edge scientific approach.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Oncology-immuno-therapy&v=1772630132911 "Schedule of future (projected) sales of companies in the market segment - Oncology immuno-therapy")
Future (projected) sales of the market as a whole
Tango Therapeutics is a biotech company using the concept of synthetic lethality to discover new targeted cancer therapies. Its valuation depends on the success of its research platform. This graph, reflecting investors' risk appetite, influences the availability of capital for funding innovative approaches in oncology.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772630132993 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Tango Therapeutics
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. While in clinical trials, the company incurs significant expenses. The chart shows its current profitability, which is an investment in the development of breakthrough drugs with the potential to generate significant profits in the future.
Market segment marginality - Oncology immuno-therapy
#VALUE!
Market marginality as a whole
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies. Its operations require significant and ongoing investment. This total return chart reflects the investment climate. During periods of economic growth, investors are more inclined to invest in breakthrough, but risky, oncology research.
Employees in the company, segment and market as a whole
Number of employees in the company Tango Therapeutics
Tango Therapeutics is a biotech company developing a new generation of targeted cancer therapies. Its team of scientists uses genetic data to discover new targets. The growth in this chart directly reflects progress in its research platform and the advancement of new candidates into clinical trials.
Share of the company's employees Tango Therapeutics within the market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company using a cutting-edge "synthetic lethality" approach to discovering new cancer drugs. Its core asset is its team of scientists. This chart shows the company's intellectual capital invested in this complex yet promising field of oncology, a measure of its scientific potential.
Number of employees in the market segment - Oncology immuno-therapy
Tango Therapeutics is developing a new generation of targeted cancer therapies based on the concept of synthetic lethality. The employment dynamics in immuno-oncology, as shown in the graph, demonstrate how cutting-edge and competitive this field is. For Tango, this means working in an environment where discoveries are made every day and competing for the best scientific minds.
Number of employees in the market as a whole
Tango Therapeutics is a biotech company specializing in developing cancer treatments. Its hiring of scientists is driven by scientific discoveries and the advancement of its drug pipeline. It represents a highly specialized, innovation-driven corner of the economy, as reflected here.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Tango Therapeutics (TNGX)
Tango Therapeutics is a biotech company developing a new class of targeted cancer drugs based on the concept of "synthetic lethality." Its business is driven by cutting-edge science. This metric reflects the enormous value the market places on the potential of this scientific platform, created by a small team of innovative scientists.
%20of%20the%20company%20Tango%20Therapeutics%20(TNGX)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Tango-Therapeutics-TNGX&v=1772630133388 "Chart of market capitalization per employee (in thousands of dollars) of the company Tango Therapeutics (TNGX)")
Market capitalization per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Tango Therapeutics is developing a new generation of targeted cancer treatments. In this cutting-edge field of biotechnology, market capitalization reflects the potential of the research platform. This metric demonstrates the enormous future value investors see in the work of each company's researcher.
%20by%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Oncology-immuno-therapy&v=1772630133415 "Market capitalization per employee (in thousands of dollars) by market segment - Oncology immuno-therapy")
Market capitalization per employee (in thousands of dollars) for the overall market
Tango Therapeutics is a biotech company working in the field of "synthetic lethality" to develop a new class of cancer drugs. The chart reflects the valuation of its cutting-edge scientific concept. The company's entire value is derived from its intellectual property platform and team of scientists. This metric demonstrates the enormous value the market places on their approach.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772630133437 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Tango Therapeutics (TNGX)
Tango Therapeutics is a biotech company using a "synthetic lethality" approach to developing cancer drugs. It is an early-stage R&D company. This graph will show a negative value—the loss (investment in R&D) per scientist. This reflects the intensity of their work on developing a new class of oncology drugs.
%20Chart%20Tango%20Therapeutics%20(TNGX)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Tango-Therapeutics-TNGX&v=1772630133485 "Company Profit Per Employee (in thousands of dollars) Chart Tango Therapeutics (TNGX)")
Profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company using a "synthetic lethality" approach to create cancer drugs. It's at the cutting edge of science. Like other R&D companies, this metric is negative. It reflects how much capital is "burned" per scientist in the process of discovering and testing new drug targets.
%20in%20the%20market%20segment%20-%20Oncology%20immuno-therapy&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Oncology-immuno-therapy&v=1772630133519 "Chart of profit per employee (in thousands of dollars) in the market segment - Oncology immuno-therapy")
Profit per employee (in thousands of dollars) for the market as a whole
Tango Therapeutics is a biotech company working in the field of "synthetic lethality" to create targeted cancer therapies. It is a preclinical/early clinical stage R&D company. It is not profitable. This chart is important to understand that in advanced oncology, employees are a cost center, creating intellectual property that (potentially) will lead to breakthroughs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772630133594 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Tango Therapeutics (TNGX)
Tango Therapeutics is a biotech company developing cancer treatments based on the concept of synthetic lethality. While in clinical trials, it does not yet have commercial products. This graph would show zero revenue, which is typical for R&D companies whose value is determined by the potential of their scientific discoveries.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Tango-Therapeutics-TNGX&v=1772630133647 "Sales chart per company employee Tango Therapeutics (TNGX)")
Sales per employee in the market segment - Oncology immuno-therapy
Tango Therapeutics (TNGX) is a biotech company using a "synthetic lethality" approach to develop targeted cancer therapies. This chart shows the average revenue per employee in the sector. For a company in the R&D stage, this is important for assessing the efficiency of capital and personnel utilization compared to other oncology biotechs.
Sales per employee for the market as a whole
Tango Therapeutics (TNGX) is a biotech company working in the field of "synthetic lethality," a cutting-edge approach in oncology. They are searching for new targets for cancer treatment. Like other companies in the R&D stage, Tango likely has no revenue. This near-zero metric reflects the high cost of maintaining an elite team of scientists working on the next generation of cancer drugs.
Short shares by company, segment and market as a whole
Shares shorted by company Tango Therapeutics (TNGX)
Tango Therapeutics (TNGX) is a biotech company using a "synthetic lethality" approach to developing new cancer treatments. It's a cutting-edge but risky field. This chart shows bearish sentiment. The high level of short positions is typical for biotech and reflects investors' bets that the company's scientific hypotheses will not be borne out in complex clinical trials. (344)
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Tango-Therapeutics-TNGX&v=1772630133729 "Short Shares Chart for the Company Tango Therapeutics (TNGX)")
Shares shorted by market segment - Oncology immuno-therapy
Tango is a biotech company working in the field of "synthetic lethality"—the search for "paired" genes to attack cancer cells. This chart reflects the general sentiment in the sector. It reflects the high investor skepticism toward early-stage oncology biotechs.
Shares shorted by the overall market
Tango Therapeutics (TNGX) is a biotech company working in the trendy field of "synthetic lethality" for cancer treatment. They're looking for vulnerabilities in cancer cells. It's cutting-edge science, but there are no guarantees. This chart shows the stakes against their scientific approach. Skeptics believe their platform won't yield results, clinical trials will fail, or the competition in this field is too intense.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Tango Therapeutics (TNGX)
Tango Therapeutics is a biotech company working in the hot field of "synthetic lethality" for cancer treatment. It's betting on a new approach to oncology. This chart measures the level of speculative interest. It shows when the stock is "overbought" due to hopes for its platform or "oversold" due to a general cooling in the biotech sector.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Tango-Therapeutics-TNGX&v=1772630133793 "RSI 14 indicator chart for the company's stock Tango Therapeutics (TNGX)")
RSI 14 Market Segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company working in the field of "synthetic lethality." This is a cutting-edge approach in oncology aimed at identifying vulnerabilities in cancer cells with specific gene mutations. This chart reflects the overall sentiment in the immuno-oncology sector. It helps assess how overheated this speculative biotech segment is.
RSI 14 for the overall market
Tango Therapeutics (TNGX) is a biotech company. Like everything in its sector, it's critically dependent on this curve. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast TNGX (Tango Therapeutics)
Tango Therapeutics (TNGX) is a biotech company developing cancer treatments using "synthetic lethality." This chart summarizes analyst opinions. It reflects their expectations regarding the success of this innovative scientific platform and progress in early clinical trials.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-TNGX-Tango-Therapeutics&v=1772630133895 "A chart showing analyst consensus forecasts for the expected stock price. TNGX (Tango Therapeutics)")
The difference between the consensus estimate and the actual stock price TNGX (Tango Therapeutics)
Tango Therapeutics is a biotech company using a synthetic lethality approach to discover and develop a new class of targeted cancer therapies. This chart shows the difference between the market's current valuation of the company and the analyst consensus target, reflecting their faith in this cutting-edge scientific platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-TNGX-Tango-Therapeutics&v=1772630133947 "A chart showing the difference between the consensus forecast and the actual stock price. TNGX (Tango Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Oncology immuno-therapy
Tango Therapeutics is a biotech company using a "synthetic lethality" approach. It targets the genetic "Achilles heels" of cancer tumors to create highly targeted drugs. This chart shows analysts' overall expectations across the oncology sector, reflecting their belief in this cutting-edge R&D approach.
Analysts' consensus forecast for the overall market share price
Tango Therapeutics is a biotech company working at the cutting edge of cancer genetics. They are searching for synthetic lethality—a way to kill cancer cells by exploiting their own genetic weaknesses. This chart shows overall market sentiment. For Tango, as an R&D company, it's important to understand how overall risk appetite (sentiment) influences funding for their complex science. (349)
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Tango Therapeutics
Tango Therapeutics (TNGX) is a clinical-stage biotech focused on synthetic lethality—a cutting-edge approach in oncology that targets cancer cells' Achilles heel. This chart represents a high-risk R&D bet. Its valuation is not tied to current revenue but rather reflects investors' faith in their scientific platform and early clinical trial data.
AKIMA Market Segment Index - Oncology immuno-therapy
Tango Therapeutics (TNGX) is a clinical-stage biotech focused on synthetic lethality (like IDEAYA); the company uses its R&D platform to discover new targets for cancer treatment. This summary metric evaluates R&D. The graph shows the segment average. This is a benchmark: how does this R&D platform (TNGX) differentiate it from the average pharma company?
The AKIM Index for the overall market
Tango Therapeutics is a biotech company using synthetic lethality to develop targeted cancer drugs. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative scientific company, currently in clinical trials, stacks up against overall economic trends and risk appetite.
